VASAMED Receives CE Mark for AcQtrac(TM) System
2006年1月5日 - 2:59AM
PRニュース・ワイアー (英語)
Noninvasive Technology to Provide Vital Information in Assessing
Cardiovascular Health of a Broad Range of Patients MINNEAPOLIS,
Jan. 4 /PRNewswire-FirstCall/ -- VASAMED (OTC:OPTL) (BULLETIN
BOARD: OPTL) , a leader in noninvasive, hemodynamic assessment
technology, announced that it received CE Mark for its new
AcQtrac(TM) System. The AcQtrac System provides real-time
measurements of hemodynamic parameters that allow physicians to
more effectively manage a broad range of cardiovascular patients.
"Each year, cardiovascular disease contributes to nearly half of
all deaths in Europe and the European Union, which represents
approximately 6 million people. Overall, heart disease is estimated
to cost Europe euro 169 billion annually," said Paulita LaPlante,
president and CEO of VASAMED. "The AcQtrac System's rapid,
noninvasive cardiovascular assessment can be a cost-effective
alternative for a market focused on earlier diagnosis and treatment
as part of their overall health policy objectives." Also cleared
for use in the United States by the FDA earlier this year, the
AcQtrac System is the next generation in noninvasive cardiovascular
assessment that provides accurate, repeatable and reliable cardiac
and circulatory health information. It relies on a unique graphical
waveform that represents the mechanical function of the
cardiovascular system and provides vital information to quickly
assess conditions such as congestive heart failure or to monitor
treatment outcomes such as those provided by drug therapy. "The
AcQtrac(TM) ICG impedance cardiograph has provided us an invaluable
tool in the management of congestive heart failure in a clinical
setting," said James Leibsohn, MD, an interventional cardiologist
at St. Luke's Medical Center, Milwaukee, Wisconsin. "We are now
able to accurately determine peripheral resistance and cardiac
output in an outpatient setting and, for the first time, adjust
medications precisely on the basis of accurate hemodynamic
measurements." In addition to the AcQtrac System, VASAMED
manufactures the SensiLase(TM) PAD 3000 and LASERDOPP(TM) PV2000
System for quantitative evaluation of microcirculatory perfusion in
patients with chronic foot ulcers, diabetes and other peripheral
arterial disease. Laser Doppler technology, coupled with
proprietary algorithms to measure skin perfusion pressure and pulse
volume, assist physicians in evaluating microvascular health and
improving blood flow and wound healing in their patients. The
accuracy of the skin perfusion pressure measurement is not affected
by edema, anemia, medial calcification or certain other conditions
that limit the usefulness of other measurement technologies.
VASAMED has also developed a system for the measurement of
sublingual CO2, which can be used in a variety of hemodynamic
diagnostic applications. For more information about VASAMED, visit
http://www.vasamed.com/ . DATASOURCE: VASAMED CONTACT: Wes
Peterson, CFO of VASAMED, +1-952-944-5857 ext. 542 Web site:
http://www.vasamed.com/
Copyright